MAPT and Alzheimer disease: Current disease-modifying therapies (DMTs) aim to alter AD progression by preventing or delaying disease development, reversing or repairing pathological changes, and include strategies that target Aβ deposition, tau hyperphosphorylation, neuroinflammation, neuronal survival, and synaptic function (Wang et al., 2024).